Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Haubrich

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
AIDS (London, England)|January 21, 2010
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patientsMiguel Goicoechea, Sonia Jain, Lucun Bi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2018
Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIVJoel Milam, Sonia Jain, Michael P Dubé, et al.
Open Forum Infectious Diseases|June 19, 2024
Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental OxygenEssy Mozaffari, Aastha Chandak, Chidinma Chima-Melton, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 17, 2014
Changes in metabolic syndrome status after initiation of antiretroviral therapySupriya Krishnan, Jeffrey T Schouten, Benjamin Atkinson, et al.
AIDS and Behavior|May 5, 2018
Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594Katya Corado, Sonia Jain, Sheldon Morris, et al.
AIDS (London, England)|August 28, 2009
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsChristine Katlama, Richard Haubrich, Jacob Lalezari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysisHeather J Ribaudo, Kimberly Y Smith, Gregory K Robbins, et al.
The Journal of Infectious Diseases|August 6, 2004
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjectsRonald Swanstrom, Ronald J Bosch, David Katzenstein, et al.
The Lancet. HIV|October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trialFranco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I MutationIgnacio Perez-Valero, Josep M Llibre, Antonella Castagna, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
AIDS (London, England)|January 21, 2010
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patientsMiguel Goicoechea, Sonia Jain, Lucun Bi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2018
Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIVJoel Milam, Sonia Jain, Michael P Dubé, et al.
Open Forum Infectious Diseases|June 19, 2024
Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental OxygenEssy Mozaffari, Aastha Chandak, Chidinma Chima-Melton, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 17, 2014
Changes in metabolic syndrome status after initiation of antiretroviral therapySupriya Krishnan, Jeffrey T Schouten, Benjamin Atkinson, et al.
AIDS and Behavior|May 5, 2018
Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594Katya Corado, Sonia Jain, Sheldon Morris, et al.
AIDS (London, England)|August 28, 2009
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsChristine Katlama, Richard Haubrich, Jacob Lalezari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysisHeather J Ribaudo, Kimberly Y Smith, Gregory K Robbins, et al.
The Journal of Infectious Diseases|August 6, 2004
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjectsRonald Swanstrom, Ronald J Bosch, David Katzenstein, et al.
The Lancet. HIV|October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trialFranco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I MutationIgnacio Perez-Valero, Josep M Llibre, Antonella Castagna, et al.
Pageof 11